基于 FAPI 的 PET 放射性同位素与[18F]FDG 在评估恶性肿瘤方面的效用比较。

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
American journal of nuclear medicine and molecular imaging Pub Date : 2024-08-25 eCollection Date: 2024-01-01 DOI:10.62347/JXZI9315
Shashi B Singh, Bimash B Shrestha, Om H Gandhi, Rajendra P Shah, Vaibhavi Mukhtiar, Cyrus Ayubcha, Vineet Desai, Christine E Eberts, Pranita Paudyal, Goody Jha, Anurag Singh, Yangyang Shi, Tushar Kumar
{"title":"基于 FAPI 的 PET 放射性同位素与[18F]FDG 在评估恶性肿瘤方面的效用比较。","authors":"Shashi B Singh, Bimash B Shrestha, Om H Gandhi, Rajendra P Shah, Vaibhavi Mukhtiar, Cyrus Ayubcha, Vineet Desai, Christine E Eberts, Pranita Paudyal, Goody Jha, Anurag Singh, Yangyang Shi, Tushar Kumar","doi":"10.62347/JXZI9315","DOIUrl":null,"url":null,"abstract":"<p><p>Fibroblast activation protein (FAP) is a type II transmembrane serine protease overexpressed in cancer-associated fibroblasts (CAFs) and has been associated with poor prognosis. PET/CT imaging with radiolabeled FAP inhibitors (FAPI) is currently being studied for various malignancies. This review identifies the uses and limitations of FAPI PET/CT in malignancies and compares the advantages and disadvantages of FAPI and <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG). Due to high uptake, rapid clearance from the circulation, and limited uptake in normal tissue, FAPI tumor-to-background contrast ratios are equivalent to or better than [<sup>18</sup>F]FDG in most applications. In several settings, FAPI has shown greater uptake specificity than [<sup>18</sup>F]FDG and improved sensitivity in detecting lymph node, bone, and visceral tissue metastases. Therefore, FAPI PET/CT may be complementary in distinguishing pathological lesions with conventional imaging, determining the primary site of malignancy, improving tumor staging, and detecting disease recurrence, especially in patients with inconclusive [<sup>18</sup>F]FDG PET/CT findings. Nevertheless, FAPI has limitations, including certain settings with non-specific uptake, modified uptake with age and menopause status, challenges with clinical access, and limited clinical evidence.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"14 4","pages":"190-207"},"PeriodicalIF":2.0000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411191/pdf/","citationCount":"0","resultStr":"{\"title\":\"The comparative utility of FAPI-based PET radiotracers over [<sup>18</sup>F]FDG in the assessment of malignancies.\",\"authors\":\"Shashi B Singh, Bimash B Shrestha, Om H Gandhi, Rajendra P Shah, Vaibhavi Mukhtiar, Cyrus Ayubcha, Vineet Desai, Christine E Eberts, Pranita Paudyal, Goody Jha, Anurag Singh, Yangyang Shi, Tushar Kumar\",\"doi\":\"10.62347/JXZI9315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fibroblast activation protein (FAP) is a type II transmembrane serine protease overexpressed in cancer-associated fibroblasts (CAFs) and has been associated with poor prognosis. PET/CT imaging with radiolabeled FAP inhibitors (FAPI) is currently being studied for various malignancies. This review identifies the uses and limitations of FAPI PET/CT in malignancies and compares the advantages and disadvantages of FAPI and <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG). Due to high uptake, rapid clearance from the circulation, and limited uptake in normal tissue, FAPI tumor-to-background contrast ratios are equivalent to or better than [<sup>18</sup>F]FDG in most applications. In several settings, FAPI has shown greater uptake specificity than [<sup>18</sup>F]FDG and improved sensitivity in detecting lymph node, bone, and visceral tissue metastases. Therefore, FAPI PET/CT may be complementary in distinguishing pathological lesions with conventional imaging, determining the primary site of malignancy, improving tumor staging, and detecting disease recurrence, especially in patients with inconclusive [<sup>18</sup>F]FDG PET/CT findings. Nevertheless, FAPI has limitations, including certain settings with non-specific uptake, modified uptake with age and menopause status, challenges with clinical access, and limited clinical evidence.</p>\",\"PeriodicalId\":7572,\"journal\":{\"name\":\"American journal of nuclear medicine and molecular imaging\",\"volume\":\"14 4\",\"pages\":\"190-207\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411191/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of nuclear medicine and molecular imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/JXZI9315\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/JXZI9315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

成纤维细胞活化蛋白(FAP)是一种在癌症相关成纤维细胞(CAF)中过度表达的 II 型跨膜丝氨酸蛋白酶,与不良预后有关。目前正在研究使用放射性标记的 FAP 抑制剂(FAPI)进行 PET/CT 成像,以治疗各种恶性肿瘤。本综述指出了 FAPI PET/CT 在恶性肿瘤中的用途和局限性,并比较了 FAPI 和 18F-氟脱氧葡萄糖([18F]FDG)的优缺点。由于摄取率高、从血液循环中清除快、在正常组织中摄取有限,在大多数应用中,FAPI 的肿瘤与背景对比度相当于或优于[18F]FDG。在一些情况下,FAPI 的摄取特异性高于[18F]FDG,在检测淋巴结、骨和内脏组织转移方面的灵敏度也有所提高。因此,FAPI PET/CT 在与常规成像区分病理病变、确定恶性肿瘤的原发部位、改善肿瘤分期和检测疾病复发方面可起到补充作用,尤其是在 [18F]FDG PET/CT 结果不确定的患者中。然而,FAPI 也有其局限性,包括某些情况下的非特异性摄取、随年龄和绝经状态而改变的摄取、临床应用方面的挑战以及有限的临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The comparative utility of FAPI-based PET radiotracers over [18F]FDG in the assessment of malignancies.

Fibroblast activation protein (FAP) is a type II transmembrane serine protease overexpressed in cancer-associated fibroblasts (CAFs) and has been associated with poor prognosis. PET/CT imaging with radiolabeled FAP inhibitors (FAPI) is currently being studied for various malignancies. This review identifies the uses and limitations of FAPI PET/CT in malignancies and compares the advantages and disadvantages of FAPI and 18F-fluorodeoxyglucose ([18F]FDG). Due to high uptake, rapid clearance from the circulation, and limited uptake in normal tissue, FAPI tumor-to-background contrast ratios are equivalent to or better than [18F]FDG in most applications. In several settings, FAPI has shown greater uptake specificity than [18F]FDG and improved sensitivity in detecting lymph node, bone, and visceral tissue metastases. Therefore, FAPI PET/CT may be complementary in distinguishing pathological lesions with conventional imaging, determining the primary site of malignancy, improving tumor staging, and detecting disease recurrence, especially in patients with inconclusive [18F]FDG PET/CT findings. Nevertheless, FAPI has limitations, including certain settings with non-specific uptake, modified uptake with age and menopause status, challenges with clinical access, and limited clinical evidence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of nuclear medicine and molecular imaging
American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
自引率
4.00%
发文量
4
期刊介绍: The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信